27806594|t|Technical Note: Bone mineral density measurements of strontium -rich trabecular bone - mimicking phantoms using quantitative ultrasound
27806594|a|Bone quantity, as determined by the current gold standard, dual energy X-ray absorptiometry (DXA), through measured areal bone mineral density (aBMD), is subject to positive biases if bone strontium levels are high. This is of particular concern for populations administered strontium-based compounds for the treatment of osteoporosis. This study investigated the dependence of bone mineral density (BMD) determinations, and associated ultrasound -determined indices, obtained by quantitative ultrasound (QUS), on bone strontium content using a new generation of trabecular bone - mimicking phantoms. A new generation of bone - mimicking phantoms, consisting of hydroxyapatite (HA) and gelatin, was developed. Castor oil layers were included in these phantoms to create a multilayer bone - mimicking phantom. These phantoms were prepared using a bone mineral fraction consisting of varying strontium concentrations in the range of 0-2.5% mol/mol as strontium-substituted HA. The effect of varying bone strontium content on determined quality indices was evaluated based on determined speed of sound (SOS), broadband ultrasound attenuation (BUA) and determined quantitative ultrasound index (QUI) for phantoms with varying BMD values and varying strontium concentration using two QUS systems: a clinical Sahara® system and an in-house research system with two identical transducers with center frequency of 1 MHz. The two QUS systems were also compared through a Bland-Altman analysis. Both the clinical system and the research QUS systems showed a strong dependency between BMD and BUA, indicating a potential for QUS to be used as a means of estimating BMD (p = 0.001). SOS was found to have no correlation to BMD (p = 0.546). There was no correlation observed between BUA and increasing bone strontium concentrations for the research (p = 0.749) and clinical (p = 0.609) QUS systems. Similarly, no dependency was observed between the SOS and bone strontium levels up to 2.5 mol/mol [Sr /(Sr + Ca)]% for the research (p = 0.862) and clinical (p = 0.481) QUS systems. No effect on the QUI values was observed with changing strontium levels with either research (p = 0.939) or clinical QUS systems (p = 0.931). A Bland-Altman analysis showed that there was a clear offset in determined QUI values for both systems but they are in agreement with one another. Bone quality can be assessed through the use of QUS while increasing bone strontium concentration was found to have no effect on QUS -determined quality indices. This study concludes that QUS can potentially be used for the determination of bone quality without introducing biases due to bone strontium levels as is known to be the case with DXA determined aBMD.
27806594	16	49	Bone mineral density measurements	T060	C0177804
27806594	53	62	strontium	T196	C0038467
27806594	69	84	trabecular bone	T024	C0222660
27806594	87	105	mimicking phantoms	T170	C0597204
27806594	112	135	quantitative ultrasound	T074	C0677475
27806594	136	140	Bone	T024	C0005931
27806594	141	149	quantity	T081	C1265611
27806594	180	193	gold standard	T080	C0150110
27806594	195	227	dual energy X-ray absorptiometry	T060	C1510486
27806594	229	232	DXA	T060	C1510486
27806594	243	278	measured areal bone mineral density	T060	C0177804
27806594	280	284	aBMD	T201	C0005938
27806594	320	324	bone	T024	C0005931
27806594	325	341	strontium levels	T059	C0524273
27806594	346	350	high	T080	C0205250
27806594	386	397	populations	T098	C1257890
27806594	398	410	administered	T169	C1521801
27806594	411	436	strontium-based compounds	T104	C0303537
27806594	445	470	treatment of osteoporosis	T061	C4303745
27806594	514	555	bone mineral density (BMD) determinations	T060	C0177804
27806594	572	582	ultrasound	T060	C0041618
27806594	595	602	indices	T170	C0918012
27806594	616	639	quantitative ultrasound	T074	C0677475
27806594	641	644	QUS	T074	C0677475
27806594	650	654	bone	T024	C0005931
27806594	655	664	strontium	T196	C0038467
27806594	665	672	content	T081	C0005963
27806594	699	714	trabecular bone	T024	C0222660
27806594	717	735	mimicking phantoms	T170	C0597204
27806594	757	761	bone	T024	C0005931
27806594	764	782	mimicking phantoms	T170	C0597204
27806594	798	812	hydroxyapatite	T121,T122,T197	C0115137
27806594	814	816	HA	T121,T122,T197	C0115137
27806594	846	856	Castor oil	T109,T121	C0007343
27806594	857	863	layers	T080	C1522408
27806594	887	895	phantoms	T170	C0597204
27806594	908	918	multilayer	T080	C1522408
27806594	919	923	bone	T024	C0005931
27806594	926	943	mimicking phantom	T170	C0597204
27806594	951	959	phantoms	T170	C0597204
27806594	982	1003	bone mineral fraction	T081	C0005963
27806594	1026	1050	strontium concentrations	T059	C0524273
27806594	1085	1109	strontium-substituted HA	T197	C0171322
27806594	1133	1137	bone	T024	C0005931
27806594	1138	1147	strontium	T196	C0038467
27806594	1148	1155	content	T081	C0005963
27806594	1170	1177	quality	T080	C0332306
27806594	1178	1185	indices	T170	C0918012
27806594	1220	1234	speed of sound	T081	C0392762
27806594	1236	1239	SOS	T081	C0392762
27806594	1242	1274	broadband ultrasound attenuation	T081	C0392762
27806594	1276	1279	BUA	T081	C0392762
27806594	1296	1325	quantitative ultrasound index	T081	C0392762
27806594	1327	1330	QUI	T081	C0392762
27806594	1336	1344	phantoms	T170	C0597204
27806594	1358	1361	BMD	T201	C0005938
27806594	1381	1404	strontium concentration	T059	C0524273
27806594	1415	1426	QUS systems	T074	C0677475
27806594	1430	1453	clinical Sahara® system	T060	C3516025
27806594	1461	1469	in-house	T078	C4288901
27806594	1470	1478	research	T062	C0035168
27806594	1479	1485	system	T074	C0677475
27806594	1505	1516	transducers	T074	C0184028
27806594	1529	1538	frequency	T079	C0439603
27806594	1557	1568	QUS systems	T074	C0677475
27806594	1598	1619	Bland-Altman analysis	T062	C0871424
27806594	1630	1645	clinical system	T060	C3516025
27806594	1654	1662	research	T062	C0035168
27806594	1663	1674	QUS systems	T074	C0677475
27806594	1691	1701	dependency	T080	C0851827
27806594	1710	1713	BMD	T201	C0005938
27806594	1718	1721	BUA	T081	C0392762
27806594	1750	1753	QUS	T074	C0677475
27806594	1790	1793	BMD	T201	C0005938
27806594	1807	1810	SOS	T081	C0392762
27806594	1847	1850	BMD	T201	C0005938
27806594	1874	1888	no correlation	T033	C0243095
27806594	1906	1909	BUA	T081	C0392762
27806594	1925	1929	bone	T024	C0005931
27806594	1930	1954	strontium concentrations	T059	C0524273
27806594	1963	1971	research	T062	C0035168
27806594	1988	1996	clinical	T080	C0205210
27806594	2009	2020	QUS systems	T074	C0677475
27806594	2072	2075	SOS	T081	C0392762
27806594	2080	2084	bone	T024	C0005931
27806594	2085	2101	strontium levels	T059	C0524273
27806594	2121	2123	Sr	T196	C0038467
27806594	2126	2128	Sr	T196	C0038467
27806594	2131	2133	Ca	T121,T123,T196	C0006675
27806594	2145	2153	research	T062	C0035168
27806594	2170	2178	clinical	T080	C0205210
27806594	2191	2202	QUS systems	T074	C0677475
27806594	2221	2224	QUI	T081	C0392762
27806594	2259	2275	strontium levels	T059	C0524273
27806594	2288	2296	research	T062	C0035168
27806594	2312	2332	clinical QUS systems	T060	C3516025
27806594	2348	2369	Bland-Altman analysis	T062	C0871424
27806594	2421	2424	QUI	T081	C0392762
27806594	2441	2448	systems	T074	C0677475
27806594	2493	2497	Bone	T024	C0005931
27806594	2498	2505	quality	T080	C0332306
27806594	2541	2544	QUS	T074	C0677475
27806594	2562	2566	bone	T024	C0005931
27806594	2567	2590	strontium concentration	T059	C0524273
27806594	2609	2618	no effect	T080	C1301751
27806594	2622	2625	QUS	T074	C0677475
27806594	2638	2645	quality	T080	C0332306
27806594	2646	2653	indices	T170	C0918012
27806594	2681	2684	QUS	T074	C0677475
27806594	2734	2738	bone	T024	C0005931
27806594	2739	2746	quality	T080	C0332306
27806594	2767	2773	biases	T078	C0600366
27806594	2781	2785	bone	T024	C0005931
27806594	2786	2802	strontium levels	T059	C0524273
27806594	2835	2838	DXA	T060	C1510486
27806594	2850	2854	aBMD	T201	C0005938